Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORACLE long-term follow-up of GT005 in geographic atrophy secondary to AMD
2024-510946-15-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Apr 2024
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of GT005 in age-related macular degeneration (AMD), sponsored by Novartis. Primary endpoint: Incidence and severity of ocular and systemic adverse events. Planned start Apr 2024; status: authorised.
02
Drugs
GT005
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2024-510946-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510946-15-00.